Nektar Investigative Site

Los Angeles, California 90057

1 studies enrolling now · 2 studies all time

What they study most

Moderate to Severe Atopic Dermatitis, Moderate-to-Severe Atopic Dermatitis

Studies at this site

• A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis — Recruiting now
• A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis — Running, not enrolling